Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 30;4(5):226-232.
doi: 10.1021/acsbiomedchemau.4c00013. eCollection 2024 Oct 16.

Development of a Polymersome Blood Ammonia Assay Coupled with a Portable Near-Infrared Fluorometer

Affiliations

Development of a Polymersome Blood Ammonia Assay Coupled with a Portable Near-Infrared Fluorometer

Marie-Lynn Al-Hawat et al. ACS Bio Med Chem Au. .

Abstract

Ammonia is a key biomarker in inborn and acquired liver disease. As clinical point-of-care blood ammonia assays are lacking, we developed a polymersome formulation for point-of-care blood ammonia sensing combined with a portable fluorometer. A pH-sensitive near-infrared (NIR) fluorescent dye was identified, which showed a strong fluorescence increase at acidic pH values. Building on reports on ammonia-selective PS-b-PEG polymersomes, these polymersomes were loaded with the NIR dye. These NIR fluorescent polymersomes sensed ammonia in a clinically relevant range in ammonia-spiked fresh whole blood with high linearity (R 2 = 0.9948) after 5 min using a conventional tabletop plate reader. Subsequently, the assay was tested with a portable fluorometer. An ammonia-dependent fluorescence increase was detected in ammonia-spiked fresh mouse blood after 5 min using the portable fluorometer. The NIR dye-loaded PS-b-PEG polymersomes rapidly sensed ammonia with high linearity in whole blood. This assay was successfully combined with a portable fluorometer and only required 3 μL of blood. These findings motivate a further development and clinical translation of this point-of-care blood ammonia assay.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following competing financial interest(s): SM is a co-inventor on a patent application related to the technology described in this study.

Figures

Figure 1
Figure 1
Polymersome ammonia assay and portable fluorometer. Mechanism of action of polymersome ammonia assay: ammonia diffuses across the membrane of transmembrane pH-gradient poly(styrene)-b-poly(ethylene glycol) polymersomes into the acidic core. The protonation of ammonia increases the luminal pH and the fluorescence intensity of an encapsulated pH-sensitive NIR fluorescent dye (A). In the proposed ammonia assay setup, capillary blood is collected by a fingerstick and added to a polymersome assay solution. The NIR fluorescence change is detected by a portable fluorometer (B). Portable fluorometer used in this study compared with an iPhone 13 as a size reference (C). NIR: near-infrared fluorescent.
Figure 2
Figure 2
pH-dependent fluorescence of IRDye 680RD. Fluorescence intensity of IRDye 680RD at different pH values detected using a tabletop plate reader (A) and a portable fluorometer (B). IRDye 680RD concentration: 2 μM. All results are mean ± SD (n = 3).
Figure 3
Figure 3
Ammonia sensing in ammonia-spiked buffer and mouse blood was carried out using a plate reader. Fluorescence intensity of IRDye 680RD-containing PS-b-PEG polymersomes at different volume fractions in ammonia-free isotonic phosphate buffer at pH 7.4 (A). Fluorescence intensity ratio of IRDye 680RD-containing PS-b-PEG polymersomes in ammonia-spiked buffer or blood over time (B). Fluorescence intensity ratio: fluorescence intensity in 0.5 mM ammonia-spiked buffer or blood normalized to nonspiked buffer or blood. Inner phase composition: dye concentration: 19 μM; buffer composition of inner phase: isotonic citric acid buffer 2.5 mM at pH 2.0; whole blood volume fraction (B): 3% (v/v); incubation at room temperature. Detector: tabletop plate reader. All results are shown as means ± SD (n = 3–4).
Figure 4
Figure 4
Ammonia sensing in ammonia-spiked mouse blood using a plate reader. Fluorescence intensity ratio of IRDye 680RD-containing PS-b-PEG polymersomes in ammonia-spiked blood over time (A). Fluorescence intensity ratio of IRDye 680RD-containing PS-b-PEG polymersomes in ammonia-spiked blood at 5 min with regression curve (B; data extracted from A). Fluorescence intensity ratio: fluorescence intensity of ammonia-spiked blood normalized to nonspiked blood. Inner phase composition: dye concentration: 37 μM; buffer composition of inner phase: isotonic citric acid buffer 2.5 mM at pH 2.0; whole blood volume fraction: 3% (v/v); incubation at room temperature. Detector: tabletop plate reader. All results are means ± SD (n = 4).
Figure 5
Figure 5
Ammonia sensing in ammonia-spiked mouse blood using a portable fluorometer. Fluorescence intensity ratio of IRDye 680RD-containing PS-b-PEG polymersomes in ammonia-spiked isotonic phosphate buffer of 50 mM at pH 7.4 over time (A). Fluorescence intensity ratio of IRDye 680RD-containing PS-b-PEG polymersomes in ammonia-spiked blood over time (B). Fluorescence intensity ratio: fluorescence intensity in ammonia-spiked buffer or blood normalized to nonspiked buffer or blood. Inner phase composition: dye concentration: 37 μM; buffer composition of inner phase: isotonic citric acid buffer 2.5 mM at pH 2.0; whole blood volume fraction (B): 3% (v/v); incubation at room temperature. Detector: portable fluorometer. All results as means ± SD (n = 4). **p < 0.01, ***p < 0.001.

References

    1. Matoori S.; Leroux J.-C. Recent advances in the treatment of hyperammonemia. Adv. Drug Delivery Rev. 2015, 90, 55–68. 10.1016/j.addr.2015.04.009. - DOI - PubMed
    1. Kroupina K.; Bémeur C.; Rose C. F. Amino acids, ammonia, and hepatic encephalopathy. Anal. Biochem. 2022, 649, 114696.10.1016/j.ab.2022.114696. - DOI - PubMed
    1. Ott P.; Vilstrup H. Cerebral effects of ammonia in liver disease: current hypotheses. Metab. Brain Dis. 2014, 29, 901–911. 10.1007/s11011-014-9494-7. - DOI - PubMed
    1. Jones B. I.; Jenkins C. A.; Murphy D.; Orr J.; Yeoman A.; Hubbuck E. R.; Heywood B. R.; Currie C. J. Predicting hepatic encephalopathy in patients with cirrhosis: A UK population–based study and validation of risk scores. Hepatol. Commun. 2023, 7, e030710.1097/hc9.0000000000000307. - DOI - PMC - PubMed
    1. Vilstrup H.; Amodio P.; Bajaj J.; Cordoba J.; Ferenci P.; Mullen K. D.; Weissenborn K.; Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014, 60, 715–735. 10.1002/hep.27210. - DOI - PubMed

LinkOut - more resources